Learn more Got it! Making therapies that make a difference Our clinical and preclinical pipeline includes wholly-owned and partnered therapeutic candidates initially targeting cancers. PIPELINE OF POTENTIAL LEAD PRODUCT CANDIDATES Zanidatamab HER2 x HER2 Bispecific Antibody PIVOTAL ZW49 HER2 x HER2 Bispecific Antibody Drug Conjugate (ADC) PHASE 1 PRECLINICAL & ADVANCED DISCOVERY Antibody Drug Conjugate (ADC) PRECLINICAL T Cell Engaging Bispecifics PRECLINICAL Microenvironment Modulators PRECLINICAL Cytokine Receptor Modulators PRECLINICAL PARTNERSHIPS Bispecific PHASE 1 Bispecific PHASE 1 * XB002 Tissue Factor ADC PHASE 1 JNJ-78278343 (CD3 x KLK2) PHASE 1 Bispecific PRECLINICAL Bispecific PRECLINICAL Bispecific PRECLINICAL Undisclosed PRECLINICAL Bispecific PRECLINICAL Bispecific PRECLINICAL *We entered into a collaboration with Celgene (which is now a Bristol-Myers Squibb company) TECHNOLOGY Azymetric™ ZymeLink™ EFECT™ ProTECT™ Science PIPELINE Zanidatamab ZW49 Preclinical Candidates Partnerships Publications For Patients INVESTORS Stock Info News Releases Events & Presentations Financials Governance CORPORATE Leadership Board of Directors Careers Legal Privacy Contact Twitter LinkedIn